Oncology Prostate and Urologic Cancers Bladder/Urothelial Localized Neoadjuvant
Categories
Protocols
HCRN-GU18-343-ABATE Phase II OPEN TO ACCRUAL
A Phase 2 Study of Cabozantinib in Combination with Atezolizumab as Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer (ABATE)